Along with the tumor burden, β2M is also a marker of kidney function.36 A better hematological response before ASCT means a lower serum level of nephrotoxic monoclonal proteins and thus a reduced kidney susceptibility to other potentially harmful insults. This evidence concerns the gene B2M and neoplasm.